Cambridge sells rest of diagnostics business:
This article was originally published in Clinica
Cambridge Biotech will sell the remainder of its diagnostics business to Carter-Wallace for $4.5 million in cash. In April, Cambridge sold the first tranche to bioMerieux Vitek (see Clinica No 700/1, p 18). Cambridge is under bankruptcy protection but about to reorganise itself into a purely pharmaceutical company. Carter-Wallace will gain four diagnostic tests for intestinal pathogens (rotavirus, adenovirus and C difficile) and one for Lyme disease. The tests will be sold through its Wampole Laboratories division.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.